|
Mutation Information
|
Mutation Site
|
V108I |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Relevant Drug
|
NNRTIs |
|
Country
|
Cameroon |
Literature Information
|
PubMed PMID
|
32843050
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2020 |
|
Journal
|
Antimicrobial resistance and infection control |
|
Title
|
First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens. |
|
Author
|
Fokam J,Takou D,Semengue ENJ,Teto G,Beloumou G,Dambaya B,Santoro MM,Mossiang L,Billong SC,Cham F,Sosso SM,Temgoua ES,Nanfack AJ,Moudourou S,Kamgaing N,Kamgaing R,Ngako Pamen JN,Etame MMN,Bissek AZ,Elat JN,Moussi EE,Colizzi V,Perno CF,Ndjolo A,VIROFORUM. |
|
Evidence
|
Prior to ART re-initiation in 2010, genotypic resistance testing (GRT) results, interpreted throughout using Stanford HIVDB (http://www.hivdb.stanford.edu) and International AIDS Society mutations list, showed the presence of one resistance associated mutation (RAM) to NRTI (V75I), two non-NRTI RAMs (K103I, V108I).
|
|
|
HIV Mutation Detail Information